Sale of QVQ Holdings BV shares -- 121
-------------------------------------------- ------ ------
Net cash used in investing activities (328) (509)
-------------------------------------------- ------ ------
Financing activities:
Proceeds on share issuance, net of
transaction costs 1,507 --
Repayment of leases (801) (715)
Proceeds on debenture issuance, net
of transaction costs 4,059 --
---------------------------------------- ------ ------
Net cash provided by (used in) financing
activities 4,765 (715)
-------------------------------------------- ------ ------
Increase (decrease) in cash during the
period 370 (1,794)
Foreign exchange (294) (468)
Cash -- beginning of the period 3,545 8,366
-------------------------------------------- ------ ------
Cash -- end of the period 3,621 6,104
-------------------------------------------- ------ ------
Cash is comprised of:
Cash 3,534 6,017
Restricted cash 87 87
-------------------------------------------- ------ ------
3,621 6,104
---------------------------------------- ------ ------
Cash paid for interest -- --
Cash paid for income tax -- --
-------------------------------------------- ------ ------
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/
CONTACT:
Investor Relations Contact
investors@ipatherapeutics.com
(END) Dow Jones Newswires
December 10, 2024 08:30 ET (13:30 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。